IFNG and focal segmental glomerulosclerosis: Furthermore, reduced levels of IL-2(+)CD3(+) and IFN-γ(+)CD3(+) in patients with FSGS were correlated with response to rituximab and were recently suggested as markers of beneficial outcome of the disease, supporting the results from our study (25).